乐伐替尼Lenvanix4(lenvatinib)

Indications for Lenvanix4(lenvatinib)
Lenvanix4(lenvatinib) is indicated for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer, and can also be used in combination with other targeted drugs for other cancers such as liver, lung, and stomach cancers.

[Lovatinib Lenvanix4(Lenvatinib) Specifications].
This product is a capsule with the specification of 4mg/10mg.

【LevatinibLenvanix4(Lenvatinib)Dosage】.
The recommended dose is 24mg (4 tablets) once daily.

[Precautions for Lenvanix4(lenvatinib)
(1) Hypertension: control blood pressure prior to treatment with Lenvanix4. Do not give Lenvanix4 for grade 3 hypertension despite optimal hypertension treatment. discontinue drug for life-threatening hypertension.
(2) Heart failure: monitor for clinical signs and symptoms of cardiac decompensation. Do not give Lenvanix4 for grade 3 cardiac insufficiency. Terminate drug for grade 4 cardiac insufficiency.
(3) Arterial thromboembolic events: terminate Lenvanix4 after one arterial thromboembolic event.
(4) Hepatotoxicity: Monitor liver function tests prior to initiation of Lenvanix4 and periodically throughout treatment. Do not administer Lenvanix4 for Grade 3 or greater hepatic impairment. discontinue treatment for hepatic failure.
(5) Proteinuria: Monitor for proteinuria prior to initiating treatment with Lenvanix4 and periodically throughout. Do not administer Lenvanix4 for 24-hour urine protein ≥ 2 g. Discontinue therapy for nephrotic syndrome.
(6) Renal failure and renal impairment: Do not administer Lenvanix4 for grade 3 or 4 renal failure/impairment.
(7) Gastrointestinal perforation and fistula formation: discontinue Lenvanix4 in patients with gastrointestinal perforation or life-threatening fistula.
(8) Prolonged QT interval: monitor and correct electrolyte abnormalities in all patients. Do not administer Lenvanix4 for the occurrence of Grade 3 or greater QT interval prolongation (5.8).
(9) Hypocalcaemia: monitor blood calcium levels at least monthly and give replacement calcium when needed.
(10) Reversible posterior leukoencephalopathy syndrome (RPLS): do not give Lenvanix4 for RPLS until complete resolution.
(11) Haemorrhagic events: do not give Lenvanix4 for grade 3 haemorrhages. discontinue treatment for grade 4 haemorrhages.
(12) Impaired thyroid-stimulating hormone suppression: monthly monitoring of TSH levels and adjustment of thyroid-replacing medications as needed in patients with DTC.
(13) Embryo-fetal toxicity: possible foetal harm. Advise against potential foetal risk and use of effective contraception.

[Lovatinib Lenvanix4 Adverse Reactions].
The most common adverse reactions to Lenvanix4 (incidence greater than or equal to 30%) were hypertension, fatigue, diarrhoea, arthralgia/myalgia, loss of appetite, weight loss, nausea, stomatitis, headache, vomiting, proteinuria, palmar and metatarsal erythema syndrome, abdominal pain, and dysphonia.

[Lovatinib Lenvanix4 for Pregnant Women
Lenvanix4 may cause fetal harm when given to a pregnant woman. Because nursing infants from Lenvanix4 have the potential for serious adverse reactions, women are advised to discontinue breastfeeding during treatment with Lenvanix4.